XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.19.1

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions | 3 Months Ended
--- | ---
Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract] |
Investment in Surface Pharmaceuticals Inc. and Agreements - Related Party Transactions | NOTE 5. INVESTMENT IN SURFACE PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS In 2017 and amended in April 2018, the Company entered into two asset purchase and license agreements (the “Surface License Agreements”) with Surface. Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights to develop, formulate, make, sell, and sub-license formulations of certain topical eye drop formulations that utilize a proprietary delivery vehicle and a proprietary doxycycline capsule (collectively, the “Surface Products”). Surface is required to make royalty payments to the Company of four to six percent (4%-6%) of net sales of the Surface Products while any patent rights remain outstanding. In January 2018, the Company and Surface entered into an amended Management Services Agreement (the “Surface MSA”), whereby the Company provided to Surface certain administrative services and support, including bookkeeping, web services and human resources related activities, and Surface paid the Company a monthly amount of $10. The Surface MSA was terminated effective July 31, 2018. As of March 31, 2019, the Company was due $50 from Surface for reimbursable expenses and amounts due under the Surface MSA and included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets. As of March 31, 2019, the Company owned 3,500,000 shares of Surface common stock (approximately 30% issued and outstanding equity interests). The Company’s director, Richard L. Lindstrom and the Company’s Chief Executive Officer, Mark L. Baum, are directors of Surface. In addition, the Company’s Chief Financial Officer, Andrew R. Boll, was a director of Surface and resigned as a director of Surface concurrent with the sale of the Surface Series A Stock. Several employees and a director of the Company (including Mr. Baum, Dr. Lindstrom and Mr. Boll) entered into consulting agreements and provided consulting services to Surface. Surface is required to make royalty payments to Dr. Lindstrom of three percent (3%) of net sales of certain Surface products while certain patent rights remain outstanding. Dr. Lindstrom is also a principal of Flying L Partners, an affiliate of the funding investor. The unaudited condensed results of operations information of Surface is summarized below:
|  | For the |
|  | Three Months Ended |
|  | March 31, 2019 |
Revenues, net |  | $ | - |
Loss from operations |  |  | 812 |
Net loss |  | $ | (812 | )
The unaudited condensed balance sheet information of Surface is summarized below:
|  | March 31, |
|  | 2019 |
Current assets |  | $ | 18,742 |
Non current assets |  |  | 49 |
Total assets |  | $ | 18,791 |
Total liabilities |  | $ | 396 |
Total stockholders’ equity |  |  | 18,395 |
Total liabilities and stockholders’ equity |  | $ | 18,791 |

X
- Definition Investments And Agreements - Related Party Transactions [Text Block] + References No definition available. + Details
Name: | HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock
Namespace Prefix: | HROW_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration